1362911-19-0

ProTAME is an inhibitor of both APC/CFzr and APC/CCdc20. Combinations of proTAME with topoisomerase inhibitors, etoposide and doxorubicin, significantly increase cell death in Multiple Myeloma (MM) cell lines and primary cells, particularly if TOPIIα levels are first increased through pre-treatment with ProTAME.

proTAME, a cell-permeable proagent form of TAME, is an anaphase promoting complex/cyclosome (APC/C) inhibitor. proTAME causes cell cycle arrest in metaphase[1][2].

[1] Lenka Radonova, et al. ProTAME Arrest in Mammalian Oocytes and Embryos Does Not Require Spindle Assembly Checkpoint Activity. Int J Mol Sci. 2019 Sep 13;20(18):4537. DOI:10.3390/ijms20184537
[2] Monika Raab, et al. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. Neoplasia. 2019 Apr;21(4):363-375. DOI:10.1016/j.neo.2019.01.007